Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Woelber L, Bommert M, Prieske K, Fischer I, Zu Eulenburg C, Vettorazzi E, Harter P, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Beckmann M, Mustea A, Meier W, Wimberger P, Hanker L, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Mahner S, Schmalfeldt B, Jaeger A. Woelber L, et al. Among authors: zu eulenburg c. Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1221-1228. doi: 10.1055/a-1120-0138. Epub 2020 Dec 3. Geburtshilfe Frauenheilkd. 2020. PMID: 33293730 Free PMC article.
Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V. Witzel ID, et al. Among authors: zu eulenburg c. J Cancer Res Clin Oncol. 2010 Nov;136(11):1709-18. doi: 10.1007/s00432-010-0829-4. Epub 2010 Mar 4. J Cancer Res Clin Oncol. 2010. PMID: 20204407
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S. Janning M, et al. Among authors: zu eulenburg c. Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4. Int J Cancer. 2019. PMID: 30694523 Free article. Clinical Trial.
Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study.
Woelber L, Bommert M, Harter P, Prieske K, Zu Eulenburg C, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Beckmann M, Mustea A, Meier W, Mahner S, Jaeger A. Woelber L, et al. Among authors: zu eulenburg c. Ann Surg Oncol. 2021 Oct;28(11):6696-6704. doi: 10.1245/s10434-021-09744-y. Epub 2021 Mar 15. Ann Surg Oncol. 2021. PMID: 33723714 Free PMC article.
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V. Witzel I, et al. Among authors: zu eulenburg c. Br J Cancer. 2012 Sep 4;107(6):956-60. doi: 10.1038/bjc.2012.353. Epub 2012 Aug 14. Br J Cancer. 2012. PMID: 22892393 Free PMC article. Clinical Trial.
Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry.
Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, Hesse T, Würschmidt F, Fehm T, Möbus V, von Minckwitz G, Loibl S, Park-Simon TW, Mueller V. Laakmann E, et al. Among authors: zu eulenburg c. Int J Mol Sci. 2016 Sep 23;17(10):1615. doi: 10.3390/ijms17101615. Int J Mol Sci. 2016. PMID: 27669228 Free PMC article.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. Nitz U, et al. Among authors: zu eulenburg c. Lancet Oncol. 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405088 Clinical Trial.
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Ihnen M, et al. Among authors: zu eulenburg c. Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31. Mol Cancer Ther. 2013. PMID: 23729402 Free PMC article.
36 results